美股異動 | 飛利浦盤前漲5% 與美國司法部達成2470萬美元和解協議了結醫療設備虛假索賠訴訟
格隆匯9月6日丨飛利浦(PHG.US)盤前漲5.5%,報17.08美元。美國司法部稱,飛利浦(PHG.US)旗下子公司Philips RS North America將支付2400萬美元,以解決有關其通過向耐用醫療設備 (DME) 供應商支付回扣來誤導聯邦醫療保健計劃的指控。根據美國司法部的聲明,Philips RS North America(前身為 Respironics)誘導DME供應商提交了虛假的呼吸機、氧氣濃縮器和其他設備的索賠。據稱,Respironics向DME供應商免費提供醫生的處方數據,這有助於他們向醫生推銷產品。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.